|
1
|
Pavkov ME and Miyamoto Y: Diabetes and
kidney disease. IDF Diabetes Atlas. 2023, https://diabetesatlas.org/resources/idf-diabetes-atlas-reports/diabetes-and-kidney-disease/.
Accessed Nov 12, 2025
|
|
2
|
Martinez Leon V, Hilburg R and Susztak K:
Mechanisms of diabetic kidney disease and established and emerging
treatments. Nat Rev Endocrinol. 22:21–35. 2026. View Article : Google Scholar
|
|
3
|
Mentz RJ, Anker SD, Pitt B, Rossing P,
Ruilope LM, Gebel M, Kolkhof P, Lawatscheck R, Rohwedder K and
Bakris GL; on behalf of the FIDELIO-DKD and FIGARO-DKD
investigators: Efficacy and safety of finerenone in patients with
chronic kidney disease and type 2 diabetes by diuretic use: A
FIDELITY analysis. Eur J Heart Fail. 27:764–774. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao H and Guo J: Macrophages in focus:
Key drivers and therapeutic opportunities in diabetic kidney
disease. Int J Biol Sci. 21:4647–4662. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naaman SC and Bakris GL: Diabetic
nephropathy: Update on pillars of therapy slowing progression.
Diabetes Care. 46:1574–1586. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mimura I, Chen Z and Natarajan R:
Epigenetic alterations and memory: Key players in the
development/progression of chronic kidney disease promoted by acute
kidney injury and diabetes. Kidney Int. 107:434–456. 2025.
View Article : Google Scholar
|
|
7
|
Mohandes S, Doke T, Hu H, Mukhi D, Dhillon
P and Susztak K: Molecular pathways that drive diabetic kidney
disease. J Clin Invest. 133:e1656542023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan X, Yang M, Lang Y, Lu S, Kong Z, Gao
Y, Shen N, Zhang D and Lv Z: Mitochondrial metabolic reprogramming
in diabetic kidney disease. Cell Death Dis. 15:4422024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong Q, Kim H, Cai GY, Chen XM, He JC and
Lee K: Modulation of TGF-β signaling new approaches toward kidney
disease and fibrosis therapy. Int J Biol Sci. 21:1649–1665. 2025.
View Article : Google Scholar
|
|
10
|
Zou Y, Yiu WH, Lok SWY, Ma J, Feng Y, Lai
KN and Tang SCW: Tubular FoxP2 and kidney fibrosis. J Am Soc
Nephrol. 36:544–558. 2025. View Article : Google Scholar
|
|
11
|
Saraswati S, Martínez P, Serrano R, Mejías
D, Graña-Castro O, Díaz RÁ, Flores JM and Blasco MA: Telomere
dysfunction in renal tubular epithelial cells leads to kidney
fibrosis. J Am Soc Nephrol. 36:2348–2363. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao L, Liang X, Liu Y, Li B, Hong M, Wang
X, Chen B, Liu Z and Wang P: Non-steroidal mineralocorticoid
receptor antagonist finerenone ameliorates mitochondrial
dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic
tubulopathy. Redox Biol. 68:1029462023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang M, Li Q, Wang S, Zuo L, Hai Y, Yuan
S, Li X, Huang X, Yang C, Yao L, et al: Astragaloside IV protects
renal tubular epithelial cells against oxidative stress-induced
injury by upregulating CPT1A-mediated HSD17B10 lysine succinylation
in diabetic kidney disease. Phytother Res. 38:4519–4540. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu YW, Chen JW, Lin LY, Huang JH, Chang CC
and Chang TT: FABP4 inhibition protects renal tubular cells and
ameliorates renal inflammation in diabetic kidney disease. Biochem
Pharmacol. 236:1168992025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hommos MS, Glassock RJ and Rule AD:
Structural and functional changes in human kidneys with healthy
aging. J Am Soc Nephrol. 28:2838–2844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bao Y, Shan Q, Lu K, Yang Q, Liang Y,
Kuang H, Wang L, Hao M, Peng M, Zhang S and Cao G: Renal tubular
epithelial cell quality control mechanisms as therapeutic targets
in renal fibrosis. J Pharm Anal. 14:1009332024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Zhang Y, Wang Y, Yang Y, Qiao Z,
Zhan P, Jin H, Xu Q, Tang W, Sun Y, et al: Tubular MYDGF slows
progression of chronic kidney disease by maintaining mitochondrial
homeostasis. Adv Sci (Weinh). 12:e24097562025. View Article : Google Scholar :
|
|
18
|
Huang H, Han Y, Zhang Y, Zeng J, He X,
Cheng J, Wang S, Xiong Y, Yin H, Yuan Q, et al: Deletion of
pyruvate carboxylase in tubular epithelial cell promotes renal
fibrosis by regulating SQOR/cGAS/STING-mediated glycolysis. Adv Sci
(Weinh). 12:e24087532025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishima N and Tanaka S: Lactate: A missing
link between metabolism and inflammation in CKD progression? Kidney
Int. 106:183–185. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu W, Guo S, Sun J, Zhao Y and Liu C:
Lactate and lactylation in cardiovascular diseases: Current
progress and future perspectives. Metabolism. 158:1559572024.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie W, He Q, Zhang Y, Xu X, Wen P, Cao H,
Zhou Y, Luo J, Yang J and Jiang L: Pyruvate kinase M2 regulates
mitochondrial homeostasis in cisplatin-induced acute kidney injury.
Cell Death Dis. 14:6632023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shao M, Chen D, Wang Q, Guo F, Wei F,
Zhang W, Gan T, Luo Y, Fan X, Du P, et al: Canagliflozin regulates
metabolic reprogramming in diabetic kidney disease by inducing
fasting-like and aestivation-like metabolic patterns. Diabetologia.
67:738–754. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Darshi M, Kugathasan L, Maity S, Sridhar
VS, Fernandez R, Limonte CP, Grajeda BI, Saliba A, Zhang G, Drel
VR, et al: Glycolytic lactate in diabetic kidney disease. JCI
Insight. 9:e1688252024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye Z, Sun Y, Yang S, Li L, Li B, Xia Y,
Yuan T, Yu W, Chen L, Zhou X and Cheng F: Lgals3 promotes calcium
oxalate crystal formation and kidney injury through histone
lactylation-mediated FGFR4 activation. Adv Sci (Weinh).
12:e24139372025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiang T, Wang X, Huang S, Zhou K, Fei S,
Zhou B, Yue K, Li Q, Xue S, Dai Y, et al: Inhibition of PKM2 by
shikonin impedes TGF-β1 expression by repressing histone
lactylation to alleviate renal fibrosis. Phytomedicine.
136:1563242025. View Article : Google Scholar
|
|
26
|
Zhang X, Chen J, Lin R, Huang Y, Wang Z,
Xu S, Wang L, Chen F, Zhang J, Pan K and Yin Z: Lactate drives
epithelial-mesenchymal transition in diabetic kidney disease via
the H3K14la/KLF5 pathway. Redox Biol. 75:1032462024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arat S, Huynh R, Kumpf S, Qian J, Shoieb
A, Virgen-Slane R, Voigt F, Xie Z and Jakubczak JL: Effects of
donor source on transcriptomic profiles of human kidney tissue.
FASEB J. 37:e228042023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mei H, Jing T, Liu H, Liu Y, Zhu X, Wang J
and Xu L: Ursolic acid alleviates mitotic catastrophe in podocyte
by inhibiting autophagic P62 accumulation in diabetic nephropathy.
Int J Biol Sci. 20:3317–3333. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leary S, Underwood W, Anthony R, Cartner
S, Grandin T, Greenacre C, Gwaltney-Brant S, McCrackin MA, Meyer R,
Miller D, et al: AVMA Guidelines for the Euthanasia of Animals:
2020 Edition. American Veterinary Medical Association; Schaumburg,
IL: 2020
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Lin XF, Cui XN, Yang J, Jiang YF, Wei TJ,
Xia L, Liao XY, Li F, Wang DD, Li J, et al: SGLT2 inhibitors
ameliorate NAFLD in mice via downregulating PFKFB3, suppressing
glycolysis and modulating macrophage polarization. Acta Pharmacol
Sin. 45:2579–2597. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhong YX, Zhao HB, Lian MH, Shen JM, Li
CX, Ma HM, Xu D, Chen GQ and Zhang C: SUMOylated hnRNPM suppresses
PFKFB3 phosphorylation to regulate glycolysis and tumorigenesis.
Cancer Lett. 616:2175732025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Z, Liang Z, Qi H, Luo X, Wang M, Du Z
and Guo W: Lactate shuttling links histone lactylation to adult
hippocampal neurogenesis in mice. Dev Cell. 60:1182–1198.e8. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang J, Wu D, Zeng F, Gu H, Li C, Cata
JP, Guo K, Miao C and Zhang H: Lactate metabolic reprogramming and
histone lactylation modification in sepsis. Int J Biol Sci.
21:5034–5055. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jung CY and Yoo TH: Pathophysiologic
mechanisms and potential biomarkers in diabetic kidney disease.
Diabetes Metab J. 46:181–197. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Das S, Devi Rajeswari V, Venkatraman G,
Elumalai R, Dhanasekaran S and Ramanathan G: Current updates on
metabolites and its interlinked pathways as biomarkers for diabetic
kidney disease: A systematic review. Transl Res. 265:71–87. 2024.
View Article : Google Scholar
|
|
37
|
Yang H, Sun J, Sun A, Wei Y, Xie W, Xie P,
Zhang L, Zhao L and Huang Y: Podocyte programmed cell death in
diabetic kidney disease: Molecular mechanisms and therapeutic
prospects. Biomed Pharmacother. 177:1171402024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu H, Li W, Hao Y, Peng Z, Zou Z and Liang
W: Baicalin ameliorates renal fibrosis by upregulating
CPT1α-mediated fatty acid oxidation in diabetic kidney disease.
Phytomedicine. 122:1551622024. View Article : Google Scholar
|
|
39
|
Yang G, Liu X, Li Y, Li L, Xiang J, Liang
Z, Jiang M and Yang S: TRIM65 as a key regulator of ferroptosis and
glycolysis in lactate-driven renal tubular injury and diabetic
kidney disease. Cell Rep. 44:1160912025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Azushima K, Kovalik JP, Yamaji T, Ching J,
Chng TW, Guo J, Liu JJ, Nguyen M, Sakban RB, George SE, et al:
Abnormal lactate metabolism is linked to albuminuria and kidney
injury in diabetic nephropathy. Kidney Int. 104:1135–1149. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng H, Pan T, Zhan M, Hailiwu R, Liu B,
Yang H and Li P: Suppression of PFKFB3-driven glycolysis restrains
endothelial-to-mesenchymal transition and fibrotic response. Signal
Transduct Target Ther. 7:3032022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bartrons R, Rodríguez-García A,
Simon-Molas H, Castaño E, Manzano A and Navarro-Sabaté À: The
potential utility of PFKFB3 as a therapeutic target. Expert Opin
Ther Targets. 22:659–674. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma J, Li X, Li Q, Sun Z, You Y, Zhang L,
Ji Z, Zhou H, Zhang Q, Wang L, et al: Niacin regulates glucose
metabolism and osteogenic differentiation via the SIRT2-C/EBPβ-AREG
signaling axis. Biomed Pharmacother. 180:1174472024. View Article : Google Scholar
|
|
44
|
Wang TT, Han T, Xiao X, Guo D, Sun X, Liu
Y, Zhao L, Xu H, Li R, Jiang L, et al: SIRT3 deficiency reduces
PFKFB3-driven T-cell glycolysis and promotes arthritic
inflammation. Sci China Life Sci. 68:1755–1769. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jiang A, Liu J, Wang Y and Zhang C:
cGAS-STING signaling pathway promotes hypoxia-induced renal
fibrosis by regulating PFKFB3-mediated glycolysis. Free Radic Biol
Med. 208:516–529. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song C, Wang S, Fu Z, Chi K, Geng X, Liu
C, Cai G, Chen X, Wu D and Hong Q: IGFBP5 promotes diabetic kidney
disease progression by enhancing PFKFB3-mediated endothelial
glycolysis. Cell Death Dis. 13:3402022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Y, Chen X, Xu X, Chen C, Min M, Liang
D, Ren J and Mao H: OTUB2 contributes to vascular calcification in
chronic kidney disease via the YAP-mediated transcription of
PFKFB3. Theranostics. 15:1185–1204. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen J, Huang Z, Chen Y, Tian H, Chai P,
Shen Y, Yao Y, Xu S, Ge S and Jia R: Lactate and lactylation in
cancer. Signal Transduct Target Ther. 10:382025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Llibre A, Kucuk S, Gope A, Certo M and
Mauro C: Lactate: A key regulator of the immune response. Immunity.
58:535–554. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang T, Ye Z, Li Z, Jing DS, Fan GX, Liu
MQ, Zhuo QF, Ji SR, Yu XJ, Xu XW and Qin Y: Lactate-induced protein
lactylation: A bridge between epigenetics and metabolic
reprogramming in cancer. Cell Prolif. 56:e134782023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu X, Yang J, Xu J, Pan H, Wang W, Yu X
and Shi S: Histone lactylation: From tumor lactate metabolism to
epigenetic regulation. Int J Biol Sci. 20:1833–1854. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li Y, Cao Q, Hu Y, He B, Cao T, Tang Y,
Zhou XP, Lan XP and Liu SQ: Advances in the interaction of
glycolytic reprogramming with lactylation. Biomed Pharmacother.
177:1169822024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li F, Si W, Xia L, Yin D, Wei T, Tao M,
Cui X, Yang J, Hong T and Wei R: Positive feedback regulation
between glycolysis and histone lactylation drives oncogenesis in
pancreatic ductal adenocarcinoma. Mol Cancer. 23:902024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sheng X, Lin H, Cole PA and Zhao Y:
Biochemistry and regulation of histone lysine L-lactylation. Nat
Rev Mol Cell Biol. 27:95–109. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liao Z, Chen B, Yang T, Zhang W and Mei Z:
Lactylation modification in cardio-cerebral diseases: A
state-of-the-art review. Ageing Res Rev. 104:1026312025. View Article : Google Scholar
|
